The people who run it shape which treatments reach patients
In mid-May 2026, the FDA's drug review division lost another senior leader, as Marty Makary's removal became the latest chapter in a broader reorganization reshaping one of America's most consequential regulatory bodies. The people who govern which medicines reach patients — and how swiftly — are being replaced, and the human stakes embedded in that process are immense. History reminds us that institutional transitions of this kind rarely stay contained within the walls where they begin.
- Marty Makary has been removed from his role overseeing FDA drug approvals, the latest in a string of senior departures that suggests a deliberate dismantling of the agency's existing leadership structure.
- The exits are creating a vacuum at the center of a regulatory body that processes thousands of drug applications annually — from novel therapies to generics to biologics — leaving approval timelines and standards in question.
- Major outlets from the New York Times to the BBC are converging on the story, each reading the shake-up differently — as instability, recalibration, or reset — but all agreeing something significant is underway.
- The unanswered questions are urgent: who fills these roles, what priorities will they bring, and whether patients awaiting new treatments will face longer waits or faster access under the incoming leadership.
Marty Makary's removal from the FDA's drug review division, announced in mid-May, is the latest in a series of leadership departures that have drawn widespread attention and raised serious questions about the future of pharmaceutical regulation in the United States.
The FDA's drug approval process is not an abstraction — it determines which treatments reach patients and how quickly. When the people running those divisions turn over in rapid succession, the effects extend far beyond the agency itself. Makary's exit follows other recent departures among senior officials overseeing drug and biologic reviews, pointing to a reorganization that goes deeper than routine personnel change.
News organizations across the spectrum — the New York Times, NBC News, the Washington Post, the BBC, and CNBC — have all covered the shake-up, framing it variously as instability or necessary reset. The breadth of coverage signals that observers recognize something substantive is being remade inside one of the federal government's most powerful regulatory bodies.
What remains unresolved is what the reorganization will ultimately mean. The FDA reviews thousands of applications each year, and its division leaders set the tone for how rigorously those applications are examined and how quickly decisions are rendered. New leadership could accelerate approvals, tighten standards, or shift institutional priorities in ways that ripple through the pharmaceutical system for years.
For patients awaiting new treatments, companies planning investments, and physicians tracking drug availability, these are not abstract concerns. The FDA's drug review divisions are being remade — and the full weight of that transformation is only beginning to come into view.
Marty Makary is no longer the head of the FDA's drug review division. The departure, announced in mid-May, represents the latest in a series of leadership changes rippling through the agency's upper ranks—a restructuring that has drawn attention from major news outlets and raised questions about the direction of pharmaceutical regulation in the United States.
Makary's removal signals something larger than a routine personnel shift. The FDA's drug approval process touches nearly every American who takes medication, and the people who run it shape which treatments reach patients and how quickly. When those positions turn over, the implications extend beyond the agency itself. His exit follows other recent departures among senior officials overseeing drug and biologic product reviews, suggesting a broader reorganization of how the FDA manages its core regulatory functions.
The timing and nature of these changes have not gone unnoticed. News organizations ranging from The New York Times to NBC News to The Washington Post have covered the shake-up, each framing it as part of a larger pattern of instability or recalibration at the federal health authority. The BBC published opinion pieces suggesting the transitions represent a necessary reset, while CNBC reported the moves as straightforward personnel news. The convergence of coverage indicates that observers across the political and journalistic spectrum recognize something substantive is happening inside the agency.
What remains unclear is the full scope of the reorganization and what it will mean for the drug approval pipeline. The FDA oversees thousands of applications each year—from new molecular entities to generic drugs to biologics. The people leading those review divisions set the tone for how rigorously applications are scrutinized, how quickly decisions are made, and what standards are applied. Leadership changes in these roles can shift timelines, alter priorities, and reshape institutional culture.
The departure of Makary and others from the drug review leadership structure leaves open questions about continuity and direction. Who will fill these roles? What experience and perspective will they bring? Will the new leadership accelerate approvals, tighten standards, or chart a different course altogether? These are not academic questions. Patients waiting for new treatments, pharmaceutical companies planning investments, and physicians trying to understand what drugs will be available all have stakes in how the FDA's leadership transitions unfold.
For now, the agency is in a state of flux. The restructuring is underway, but its full effects remain to be seen. What is certain is that the FDA's drug review divisions—among the most consequential regulatory bodies in American government—are being remade, and the implications will reverberate through the pharmaceutical system for years to come.
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter who runs the FDA's drug division? It's just bureaucracy, right?
Not quite. The person in that role decides how fast drugs move through approval, what evidence is required, how much risk is acceptable. They set the culture for thousands of reviewers. That shapes what medicines reach patients and when.
So Makary was doing something wrong, or just in the way?
The sources don't say he did anything wrong. This looks more like a deliberate restructuring—multiple leaders leaving at once suggests a planned reorganization, not a firing for cause.
What would change if new leadership came in with different priorities?
Everything downstream. Approval timelines could shift. Standards for evidence could tighten or loosen. The speed at which a cancer drug or rare disease treatment reaches patients could accelerate or slow. Pharmaceutical companies would adjust their strategies based on what they expect the new leadership to do.
Is this unusual?
Leadership changes happen, but the coverage suggests this is part of a broader shake-up, not an isolated departure. When multiple senior officials leave the drug review divisions at once, it signals something intentional is happening.
Who benefits from this kind of change?
That depends entirely on what the new leadership does. If they streamline approvals, patients waiting for treatments might benefit. If they tighten standards, public safety might be better protected. Right now, no one knows which direction this goes.